| Literature DB >> 32670599 |
Behnam Liaghat1, Søren T Skou1,2, Uffe Jørgensen3, Jens Sondergaard4, Karen Søgaard5,6, Birgit Juul-Kristensen1.
Abstract
BACKGROUND: People with hypermobility spectrum disorder (HSD) are in great risk of experiencing shoulder symptoms, but evidence for treatment is sparse. Therefore, the objective was to evaluate the feasibility of 16-week shoulder strengthening programme for improving shoulder strength and function in people with HSD and shoulder symptoms for more than 3 months to inform a future randomised controlled trial (RCT).Entities:
Keywords: Hypermobility; Hypermobility spectrum disorder; Shoulder; Strength; WOSI
Year: 2020 PMID: 32670599 PMCID: PMC7350677 DOI: 10.1186/s40814-020-00632-y
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Fig. 1The exercise programme included five exercises targeting scapular and rotator cuff muscles. A1-A2: sidelying external rotation (ER) in neutral, B1-B2: prone horizontal abduction, C1-C2: prone ER in 90° of shoulder abduction, D1-D2: supine scapular protraction, and E1-E2: seated shoulder elevation in the scapular plane
Research progression criteria for continuing to the definitive randomised controlled trial
| Outcome | Green | Amber | Red |
|---|---|---|---|
| Participant recruitment | Inclusion rate of one participant per general practitioner or physiotherapist every month (approximately | ( | No recruitment after 2 months |
| Completion of the outcome measures | Mean < 120 min to complete all objective outcome measures, and that at least 67% of participants found the duration acceptable. | Between 121 and 150 min, or only 50–66% of participants found the duration acceptable. | > 150 min or < 50% of participants found the duration acceptable |
| Participant retention | 10 or more participants show up at 16-week follow up | Only 6–9 participants show up at 16-week follow up. | Below 6 participants show up at 16-week follow up. |
| Adherence to exercise intervention | Minimum 75% of participants adhering to at least 75% of exercise sessions. | Only 50–75% of participants adhering to 50–75% of exercise sessions. | < 50% of participants adhering to < 50% of exercise sessions |
| Adverse events | No or minor adverse events with no participants discontinuing the study | Minor or serious adverse events leading to 2 or less participants discontinuing the study | Serious adverse events leading to > 2 participants discontinuing the study |
Research progression criteria were based on a traffic light system of green (go), amber (amend) and red (stop) [24]. Results of these research progression criteria were evaluated by the research group, who recommended whether to proceed with the definitive randomised controlled trial, and which amendments that needed to be made before proceeding
Fig. 2Flow diagram of participant enrolment, allocation, follow up and analysis
Baseline demographic and clinical characteristics for participants with hypermobility spectrum disorder (HSD) and long-lasting shoulder symptoms (n = 12)
| Characteristic | |
|---|---|
| Age, years | 39.3 ± 13.9 |
| Sex (females/males) | 11/1 |
| Height, cm | 168.0 ± 7.6 |
| Weight, kg | 73.8 ± 13.5 |
| Hypermobility spectrum disorder (HSD) | |
| Beighton score, 0–9 | 4.5 ± 1.2 |
| 5PQ, 0–5 | 3.4 ± 1.1 |
| Historical HSD, | 6 (50.0) |
| Generalised HSD, | 6 (50.0) |
| Symptom duration, months | 36 [15-66] |
| Shoulder pain at inclusion, | 11 (91.7) |
| Previous shoulder dislocation, | 3 (25.0) |
| WOSI total score, 0–2100 | 1037 ± 215 |
| IPAQ short version (high, moderate, low), | 7 (58.3), 2 (16.7), 3 (25.0) |
Data are presented as mean ± standard deviation, median [interquartile range], or number (percentage)
5PQ 5-part questionnaire, WOSI Western Ontario Shoulder Instability Index, IPAQ The International Physical Activity Questionnaire
Primary outcomes in research progression criteria to inform the definitive randomised controlled trial
| Research progression criteria | Evaluation | |
|---|---|---|
| Participant recruitment rate ( | 5.6 | Amber (amend) |
| Completion of baseline outcome measures | ||
| Assessment duration including screening (min, mean ± SD) | 105 ± 9 | Green (go) |
| Participants answering acceptable duration ( | 12 (100.0) | Green (go) |
| Participant retention | ||
| Participants who completed the follow up ( | 12 (100.0) | Green (go) |
| Adherence to exercise intervention | ||
| Participants adhering to exercise programme ( | 10 (83.3) | Green (go) |
| Adverse events | ||
| Minor events ( | 4 (33.3) | Green (go) |
| Serious events ( | 0 | Green (go) |
| Participants discontinuing the study ( | 0 | Green (go) |
These research progression criteria were based on a traffic light system of green (go), amber (amend) and red (stop) [24]
Fig. 3The Western Ontario Shoulder Instability Index (WOSI) total score for every participant from baseline to follow up after 16 weeks of heavy shoulder strengthening exercise programme
Secondary treatment outcomes in participants with hypermobility spectrum disorder and long-lasting shoulder symptoms (n = 12)
| Baseline | Follow up | Within-group mean change (95% CI) | Within-group mean %—improvement | |
|---|---|---|---|---|
| Self-reported outcome measures | ||||
| WOSI total score, 0–2100 | 1037 ± 215 | 509 ± 365 | − 528 (− 738, − 318) | 51 |
| Physical symptoms, 0–1000 | 455 ± 104 | 211 ± 151 | − 245 (− 337, − 152) | 54 |
| Sports/recreation/work, 0–400 | 228 ± 65 | 112 ± 97 | − 117 (− 172, − 61) | 51 |
| Lifestyle, 0–400 | 151 ± 94 | 84 ± 79 | − 67 (− 113, − 22) | 44 |
| Emotions, 0–300 | 203 ± 43 | 103 ± 72 | − 100 (− 159, − 40) | 49 |
| Shoulder pain (NPRS) during the past 7 days | ||||
| Lowest, 0–10 | 1.7 ± 1.4 | 0.8 ± 1.1 | − 0.9 (− 1.7, − 0.2) | 53 |
| Highest, 0–10 | 5.4 ± 2.6 | 2.9 ± 2.3 | − 2.5 (− 3.8, − 1.2) | 46 |
| Average, 0–10 | 3.5 ± 1.9 | 1.1 ± 1.2 | − 2.4 (− 3.7, − 1.2) | 69 |
| CIS, fatigue subscale, 8–56 | 39 ± 12 | 30 ± 11 | − 9 (− 16, − 2) | 23 |
| COOP/WONCA, 6–30 | 14.3 ± 3.7 | 13.2 ± 3.8 | − 1.2 (− 4.5, 2.1) | 8 |
| Tampa Scale of Kinesiophobia, 11–44 | 25.5 ± 4.4 | 22.3 ± 4.3 | − 3.3 (− 5.7, − 0.8) | 13 |
| Global Perceived Effect, − 5 to 5 | – | 3.5 [3-5] | – | – |
| EQ-5D-3L Health status questionnaire | ||||
| EQ-VAS, 0–100 | 68 ± 17 | 75 ± 16 | 7 (− 7, 21) | 10 |
| Index score, < 0–1 | 0.80 ± 0.10 | 0.81 ± 0.10 | 0.01 (− 0.08, 0.09) | 1 |
| Objective outcome measures | ||||
| Range of motion, ° | ||||
| Internal rotation passive | 66.4 ± 18.8 | 57.5 ± 7.7 | − 8.9 (− 18.8, 0.9) | 13 |
| Internal rotation active | 62.3 ± 16.3 | 58.7 ± 8.2 | − 3.5 (− 12.4, 5.3) | 6 |
| External rotation passive | 100.9 ± 27.3 | 100.9 ± 17.0 | − 0.1 (− 13.3, 13.2) | 0 |
| External rotation active | 101.7 ± 22.3 | 103.6 ± 13.8 | 1.9 (− 9.3, 13.1) | − 2 |
| Total rotation test > 180° | 5 (42) | 1 (8) | ||
| Isometric shoulder strength, Nm/kg | ||||
| Scaption ( | 1.67 ± 0.72 | 2.18 ± 0.76 | 0.51 (0.23, 0.78) | 31 |
| Internal rotation ( | 4.57 ± 1.71 | 5.90 ± 1.41 | 1.32 (0.70, 1.95) | 29 |
| External rotation( | 3.17 ± 1.22 | 4.05 ± 1.02 | 0.89 (0.37, 1.40) | 28 |
| External/internal rotation ratio ( | 0.72 ± 0.17 | 0.69 ± 0.10 | − 0.02 (− 0.10, 0.05) | − 3 |
| Proprioception in flexion, error (°) | ||||
| Low range, 55° ± 10° | 4.9 ± 1.7 | 3.6 ± 1.4 | − 1.2 (− 2.4, 0.0) | 24 |
| Mid-range, 90° ± 10° | 4.3 ± 2.0 | 3.4 ± 1.5 | − 0.9 (− 2.2, 0.3) | 21 |
| High range,125° ± 10° ( | 4.3 ± 2.0 | 4.9 ± 3.2 | 0.6 (− 2.0, 3.2) | − 14 |
| Shoulder instability and laxity tests, positive, | ||||
| Shoulder flexion test | 1 (8.3) | 2 (16.7) | ||
| Apprehension test | 6 (50.0) | 4 (33.3) | ||
| Relocation test | 5 (41.7) | 2 (16.7) | ||
| Release test | 4 (33.3) | 2 (16.7) | ||
| Load and shift anterior (0–3), positive 2–3 | 5 (41.7) | 8 (66.7) | ||
| Load and shift posterior (0–3), positive 2–3 | 0 (0.0) | 0 (0.0) | ||
| Sulcus sign, positive > 2 cm | 0 (0.0) | 0 (0.0) | ||
| Gagey, positive > 105° | 4 (33.3) | 1 (8.3) | ||
| Rotés Queról, positive > 90° | 4 (33.3) | 0 (0.0) | ||
Data are presented as mean ± SD, median [IQR], and n (%)
SD standard deviation, IQR interquartile range, CI confidence interval, WOSI Western Ontario Shoulder Instability Index, NPRS numeric pain rating scale, CIS Checklist Individual Strength, COOP/WONCA Dartmouth Primary Care Cooperative Research Network/World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians, EQ-5D-3L European Quality of life - 5 Dimensions – Three-Level, VAS visual analogue scale